Journal of Immunological Techniques & Infectious Diseases ISSN: 2329-9541

Review Article, J Immunol Tech Infect Dis Vol: 4 Issue: 1

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

Subhajit Dasgupta1* and Mausumi Bandyopadhyay2
1Department of Microbiology, Immunology and Department of Biochemistry, Saint James School of Medicine, Albert Lake drive, The Quarter, A-I-2640, P.O Box 318, Anguilla BWI, Anguilla
2Biological Sciences, Trident Technical College, North Charleston, South Carolina 29406, USA
Corresponding author : Subhajit Dasgupta
Department of Microbiology, Immunology, Saint James School of Medicine, Albert Lake Drive, The Quarter, P.O Box 318, A-I-2640, Anguilla BWI, Anguilla
Tel: +1-264-497-5125
E-mail: [email protected]
Received: November 19, 2014 Accepted: January 15, 2015 Published: January 19, 2015
Citation: Subhajit D, Mausumi B (2015) Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis. J Immunol Tech Infect Dis 4:1. doi:10.4172/2329-9541.1000131

Abstract

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.

Keywords: Multiple sclerosis; CD52; Lymphocytes; Monoclonal antibody; Alemtuzumab

Track Your Manuscript

Share This Page

Media Partners